Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 801 - 825 of 8179 in total
Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells. Avelumab was first approved by the FDA on March 23, 2017. On September 18 and December 18 of the same year,...
Approved
Investigational
Matched Description: … It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell ... [A261496] On September 18 and December 18 of the same year, it was also granted approval by EMA [L48126 …
A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
Approved
Investigational
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral...
Approved
Matched Description: … of nucleic acid chains. ... Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding ... This modification prevents the formation of phosphodiester linkages which are needed for the completion …
A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.
Approved
Lucinactant is a new synthetic peptide-containing surfactant for intratracheal use. It contains sinapultide, a novel, hydrophobic, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human surfactant protein-B (SB-P). More specifically, it mimics the C-terminal amphipathic helical domain of this protein. It also consists of phospholipids...
Approved
Investigational
Matched Description: … It is completely devoid of animal-derived components. FDA approved on March 6, 2012. ... More specifically, it mimics the C-terminal amphipathic helical domain of this protein. ... It also consists of phospholipids (dipalmitoylphosphatidylcholine, DPPC and palmitoyloleoyl phosphatidylglycerol …
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … advance in migraine headache treatment and may become the new standard of therapy in the treatment of ... Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. ... first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence...
Approved
Matched Description: … memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. ... This defence includes the production of humoral immunity through the development of antibodies (through ... A seasonally-specific component of the influenza vaccine. …
Delandistrogene moxeparvovec is an adeno-associated virus vector-based gene therapy developed by Sarepta Therapeutics. It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD). DMD is an X-linked genetic disorder characterized by mutations in the dystrophin gene, leading...
Approved
Investigational
Matched Description: … Microdystrophin is a truncated, functional form of dystrophin.[A260256, L47021] ... protein responsible for muscle function; thus, patients with DMD experience a progressive deterioration of ... virus serotype rh74 (AAVrh74) based vector containing the microdystrophin transgene under the control of
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in...
Approved
Investigational
Matched Description: … the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of
An adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of norepinephrine. It has been used primarily as a vasoconstrictor in the treatment of hypotension.
Approved
Investigational
Matched Description: … It has been used primarily as a vasoconstrictor in the treatment of hypotension. ... adrenergic agonist that acts predominantly at alpha adrenergic receptors and also stimulates the release of
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Description: … Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. ... Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus …
Propylhexedrine is an alpha-adrenergic agonist often used in nasal decongestant inhalers. It is used to give temporary relief for nasal congestion from colds, allergic rhinitis, or allergies.
Approved
Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the...
Approved
Matched Description: … Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. ... [L1117] Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq …
Approved
Vet approved
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational
Matched Description: … Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia ... Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of ... It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake …
Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by T. brucei gambiense and T. brucei rhodesiense, remains a moderate risk (>1/10,000 inhabitants per year in endemic areas) despite focussed control efforts. Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first...
Approved
Investigational
Matched Description: … Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … antibodies were important for therapeutic benefit in animal models of EBOV infection. ... _ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of ... [A222078] The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also …
Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%. Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid...
Approved
Matched Description: … antibodies were important for therapeutic benefit in animal models of EBOV infection. ... _ genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of ... [A222078] The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also …
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its...
Approved
Vet approved
Matched Description: … overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of ... combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of
Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about...
Approved
Nutraceutical
Vet approved
Matched Description: … Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors ... of melatonin synthesis. ... the circadian rhythms of several biological functions, including the sleep-wake cycle. …
Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema, bronchoconstriction, and tachycardia. Acrivastine is...
Approved
Matched Description: … Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever ... As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby …
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to...
Approved
Investigational
Matched Description: … [L6658] The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody …
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Approved
Matched Description: … It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the …
Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
Approved
Matched Description: … It is used for a variety of fungal infections, mainly topically. [PubChem] …
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Approved
Matched Description: … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes …
Displaying drugs 801 - 825 of 8179 in total